|
Variables
|
Control
|
Dox
|
Vitamin E Telmisartan
|
P value
|
|---|
|
End-systolic Volume (uL)
|
43.64 ± 1.23
|
69.61 ± 2.36
|
51.34 ± 1.22
|
<0.05
|
|
End-diastolic Volume (uL)
|
69.61 ± 2.37
|
85.03 ± 3.53
|
63.21 ± 1.43
|
<0.05
|
|
End-systolic Pressure (mmHg)
|
70.57 ± 1.22
|
56.64 ± 6.76
|
64.65 ± 1.75
|
<0.05
|
|
End-diastolic Pressure (mmHg)
|
8.36 ± 1.19
|
3.42 ± 0.36
|
7.14 ± 1.54
|
<0.05
|
|
Ejection Fraction (%)
|
42.34 ± 3.21
|
17.35 ± 0.57
|
25.43 ± 1.21
|
<0.05
|
|
Cardiac Output (ml/min)
|
12.67 ± 1.26
|
6.03 ± 0.4
|
7.83 ± 1.17
|
<0.51
|
|
E MAX
|
21.38 ± 2.36
|
14.34 ± 1.32
|
16.43 ± 1.
|
<0.51
|
- P < 0.05, statistically differences between Dox treated only group and with Vitamin E, and Telmisartan treatment; (n = 8 per group).
